Another FDA approval in Aurobindo's kitty

Aurobindo Pharma receives FDA approval for methylprednisolone sodium succinate injection

approved-29149-1280

The approval is for the strength 40 mg/vial, 125 mg/vial, 500 mg/vial, and 2 g/vial

Aurobindo Pharma has received final approval from the US Food and Drug Administration (US FDA) to manufacture and market Methylprednisolone Sodium Succinate Injection USP, 40 mg/vial, 125 mg/vial, 500 mg/vial, and 2 g/vial.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Solu-Medrol, of Pharmacia and Upjohn.

Methylprednisolone Sodium Succinate Injection is a lyophilized product used in the treatment of various medical conditions viz allergic states, disorders etc. The approved product has an estimated market size of $102 million for the twelve months ending October 2015, according to IMS.

 

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X